- Home
- RMAX vs GOSS Comparison
RMAX vs GOSS Comparison
Compare RMAX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- GOSS
- Stock Information
- Founded
- RMAX 1973
- GOSS 2015
- Country
- RMAX United States
- GOSS United States
- Employees
- RMAX N/A
- GOSS N/A
- Industry
- RMAX Real Estate
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- GOSS Health Care
- Exchange
- RMAX Nasdaq
- GOSS Nasdaq
- Market Cap
- RMAX 161.9M
- GOSS 188.6M
- IPO Year
- RMAX 2013
- GOSS 2019
- Fundamental
- Price
- RMAX $7.29
- GOSS $0.84
- Analyst Decision
- RMAX Hold
- GOSS Strong Buy
- Analyst Count
- RMAX 1
- GOSS 4
- Target Price
- RMAX $10.50
- GOSS $7.50
- AVG Volume (30 Days)
- RMAX 151.0K
- GOSS 1.5M
- Earning Date
- RMAX 05-01-2025
- GOSS 05-06-2025
- Dividend Yield
- RMAX N/A
- GOSS N/A
- EPS Growth
- RMAX N/A
- GOSS N/A
- EPS
- RMAX 0.37
- GOSS N/A
- Revenue
- RMAX $307,685,000.00
- GOSS $114,701,000.00
- Revenue This Year
- RMAX N/A
- GOSS N/A
- Revenue Next Year
- RMAX $1.25
- GOSS $172.31
- P/E Ratio
- RMAX $19.70
- GOSS N/A
- Revenue Growth
- RMAX N/A
- GOSS N/A
- 52 Week Low
- RMAX $6.90
- GOSS $0.50
- 52 Week High
- RMAX $14.31
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- RMAX 34.80
- GOSS 37.58
- Support Level
- RMAX $7.22
- GOSS $0.80
- Resistance Level
- RMAX $7.87
- GOSS $0.88
- Average True Range (ATR)
- RMAX 0.44
- GOSS 0.10
- MACD
- RMAX -0.03
- GOSS -0.01
- Stochastic Oscillator
- RMAX 24.53
- GOSS 20.24
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.